Tag

Blood cancer
The Australasian Myeloma Research Consortium (AMaRC) in collaboration with theAustralasian Leukaemia & Lymphoma Group (ALLG) and the Myeloma and Related DiseasesRegistry (MRDR) is conducting a phase II study to investigate the optimal usage oflenalidomide and/or bortezomib in newly-diagnosed transplant-ineligible myeloma patientsbased on a frailty score (frailty is characterised by a decline in body functions). If...
Continue Reading
Myeloma experts convened in person and online for the 2022 Multiple Myeloma Queenstown Summit, hosted by Myeloma New Zealand. This year’s meeting included presentations from local and international experts, including the Chief Medical Officer of the International Myeloma Foundation, Professor Joseph Mikhael, Assistant Professor Jonathan Keats from Arizona, and Professor Simon Harrison and Dr Simon...
Continue Reading
MEDIA RELEASE 7 September 2022 New Zealanders living with multiple myeloma, a deadly, relapsing/remitting blood cancer, are mounting a major, evidence-based campaign to press Pharmac into funding a transformative treatment that has been standard-of-care throughout the OECD for more than 5 years.    Myeloma patient and trustee of Myeloma NZ Nichola Oakenfull says patients who’ve...
Continue Reading
OPINION: How long does it take you to make a decision about whether or not to buy something? You’ve got all the information in front of you. You know it’s a good product. It works. You need it. And you’ve got the money to buy it. So how long will it take? What if I said...
Continue Reading
In August 2022, Myeloma New Zealand is hosting its 4th Myeloma Summit for medical professionals in Queenstown. Held in 2016,2018, 2020 and now again in 2022, the Summit brings together medical professionals involved with Myeloma in NZ to share and to learn from one another and from the international speakers who join the meeting.  This year...
Continue Reading
MEDIA RELEASE DOCTOR CALLS ON MINISTER LITTLE TO RELEASE ‘BURIED’ INDEPENDENT REPORT ON PHARMAC The final report of the Independent Pharmac Review Panel has been sitting with Health Minister Andrew Little since February, with no reason offered for why it has not been released, says Myeloma NZ Chief Executive Dr Ken Romeril. “Given the damning...
Continue Reading
The Cancer Control Agency’s analysis of the gap between Australia and New Zealand in funding 18 selected medicines with substantial clinical benefit is a welcome way of drawing attention to the plight of NZ cancer patients desperate for treatments that are funded across the Tasman, but not here, says Myeloma NZ Chief Executive Dr Ken...
Continue Reading
This link here: Te Aho o Te Kahu – Cancer during COVID-19 contains information for patients and whānau with cancer. Cancer treatment continues at all phases of the Ministry of Health’s Omicron Response Plan.
Continue Reading
1 2

Floor 7, 90 The Terrace
Wellington Central
New Zealand